Interprotein Corporation – Product Pipeline Review – 2012

Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Interprotein Corporation Snapshot 5
Interprotein Corporation Overview 5
Key Information 5
Key Facts 5
Interprotein Corporation – Research and Development Overview 6
Key Therapeutic Areas 6
Interprotein Corporation – Pipeline Review 8
Pipeline Products by Stage of Development 8
Pipeline Products – Monotherapy 9
Interprotein Corporation – Pipeline Products Glance 10
Interprotein Corporation – Early Stage Pipeline Products 10
Pre-Clinical Products/Combination Treatment Modalities 10
Discovery Products/Combination Treatment Modalities 11
Interprotein Corporation – Drug Profiles 12
IgE Inhibitor 12
Product Description 12
Mechanism of Action 12
R&D Progress 12
IL-6 Inhibitor 13
Product Description 13
Mechanism of Action 13
R&D Progress 13
IPC-003 14
Product Description 14
Mechanism of Action 14
R&D Progress 14
Notch 1 Inhibitor 15
Product Description 15
Mechanism of Action 15
R&D Progress 15
Vascular Endothelial Growth Factor Inhibitor 16
Product Description 16
Mechanism of Action 16
R&D Progress 16
Zinc Regulator 17
Product Description 17
Mechanism of Action 17
R&D Progress 17
Interprotein Corporation – Pipeline Analysis 18
Interprotein Corporation – Pipeline Products by Therapeutic Class 18
Interprotein Corporation – Pipeline Products By Target 19
Interprotein Corporation – Pipeline Products by Route of Administration 20
Interprotein Corporation – Pipeline Products By Mechanism of Action 21
Interprotein Corporation – Recent Pipeline Updates 22
Interprotein Corporation – Locations And Subsidiaries 23
Head Office 23
Financial Deals Landscape 24
Interprotein Corporation, Deals Summary 24
Interprotein Corporation, Pharmaceuticals & Healthcare, Deal Details 25
Partnerships 25
Interprotein Enters Into Co-Development Agreement With Takeda Pharma 25
LegoChem Biosciences Enters Into Collaboration Agreement With Interprotein 26
Interprotein Enters Into Drug Discovery Agreement With Ajinomoto Pharma 27
Evotec Enters Into Co-Development Agreement With Interprotein 28
Appendix 29
Methodology 29
Coverage 29
Secondary Research 29
Primary Research 29
Expert Panel Validation 29
Contact Us 30
Disclaimer 30

List of Tables
Interprotein Corporation, Key Information 5
Interprotein Corporation, Key Facts 5
Interprotein Corporation – Pipeline by Indication, 2012 7
Interprotein Corporation – Pipeline by Stage of Development, 2012 8
Interprotein Corporation – Monotherapy Products in Pipeline, 2012 9
Interprotein Corporation – Pre-Clinical, 2012 10
Interprotein Corporation – Discovery, 2012 11
Interprotein Corporation – Pipeline By Therapeutic Class, 2012 18
Interprotein Corporation - Pipeline By Target, 2012 19
Interprotein Corporation – Pipeline By Route of Administration, 2012 20
Interprotein Corporation – Pipeline Products By Mechanism of Action, 2012 21
Interprotein Corporation – Recent Pipeline Updates, 2012 22
Interprotein Corporation, Deals Summary 24
Interprotein Enters Into Co-Development Agreement With Takeda Pharma 25
LegoChem Biosciences Enters Into Collaboration Agreement With Interprotein 26
Interprotein Enters Into Drug Discovery Agreement With Ajinomoto Pharma 27
Evotec Enters Into Co-Development Agreement With Interprotein 28

List of Figures
Interprotein Corporation – Pipeline by Indication, 2012 7
Interprotein Corporation – Pipeline by Stage of Development, 2012 8
Interprotein Corporation – Monotherapy Products in Pipeline, 2012 9
Interprotein Corporation – Pipeline By Therapeutic Class, 2012 18
Interprotein Corporation - Pipeline By Target, 2012 19
Interprotein Corporation - Pipeline Products By Mechanism of Action, 2012 21